BB-1709
- Generic Name
- BB-1709
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT06241898
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath